GLP-based treatments may support healthier metabolic function, improved insulin sensitivity, reduced inflammation, digestive health, and long-term wellness goals
If youve been taking a GLP-1 medication consistently and arent seeing the results you expected, its worth discussing alternative treatment options with a bariatric specialist
Selyutina et al., 2016)
Boards of pharmacy, drug maker taking action In late April, the FDA recognized that some compounders were substituting untested and unproven salt forms of semaglutide (ie, semaglutide sodium and semaglutide acetate) rather than its base form
Liver fat fraction, measured by MRI-PDFF in a subgroup, decreased substantially, supporting a potential role in MASLD management
100% of patients in the REVEAL-1 Cohort maintained at least 5% of GLP-1-induced weight loss through one year: This 5% threshold is the responder definition used as the second co-primary endpoint in the REMAIN-1 Pivotal Cohort, which evaluates a responder rate among the Revita treated participants at one year to assess the durability of the Revita procedure for weight maintenance after GLP-1 discontinuation